Evidence map›Paper›PMID 40950859›Full record

ArticleJournal of thoracic disease2025

Safety and efficacy of co-ablation

Yufeng Wang, Runqi Guo, Zhixin Bie, Bin Li, Xiaoguang Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yufeng WangDepartment of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Runqi GuoDepartment of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Zhixin BieDepartment of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Bin LiDepartment of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Xiaoguang LiDepartment of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ablation is an effective alternative treatment option for early-stage non-small cell lung cancer (NSCLC) patients who are not candidates for surgery or who refuse surgery. Microwave ablation (MWA) and cryoablation (CA) are both minimally invasive treatment techniques widely used in NSCLC patients, and their safety and efficacy have been verified. This study aimed to compare the safety and efficacy of co-ablation (Co-A) and MWA in the treatment of subpleural stage I NSCLC. Methods: From December 2023 to December 2024, a retrospective analysis was conducted on 87 eligible patients (40 males, 47 females; mean age ± standard deviation: 72.03±9.07 years; age range, 31-88 years). Patients were divided into two groups based on the treatment method: a Co-A group and an MWA group. Recurrence-free survival (RFS) rates and complication rates were compared between the two groups. Results: Co-A had a significantly longer mean operative time compared to MWA (28.26±7.56 Conclusions: Compared with MWA, Co-A demonstrates no significant difference in efficacy or safety for treating patients with subpleural stage I NSCLC, but is associated with reduced perioperative pain and a longer operative duration.

Indexed as

co-ablation (Co-A)Microwave ablation (MWA)non-small cell lung cancer (NSCLC)subpleural

Identifiers

PMID40950859
PMCPMC12433110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.